Novartis Acquires Avidity Biosciences
Novartis has entered a $12 billion definitive merger agreement to acquire Avidity Biosciences, enhancing its RNA therapeutics pipeline for rare neuromuscular diseases.
Avidity’s pioneering AOC platform for RNA therapeutics and its late-stage assets bolster our commitment to delivering innovative, targeted and potentially first-in-class medicines to treat devastating, progressive neuromuscular diseases.
Vas Narasimhan, CEO of Novartis, praised Avidity's team for building robust programs with industry-leading delivery of RNA therapeutics to muscle tissue.
The acquisition follows the separation of Avidity’s early-stage precision cardiology programs into a new publicly traded company, SpinCo.
Author's summary: Novartis acquires Avidity Biosciences for $12 billion.
More News
- Cultivated Chicken by PARIMA Gains Regulatory Approval From the Singapore Food Agency - vegconomist - the vegan business magazine
- Kaishan signs steam supply agreement for 165-MW geothermal green ammonia facility in Kenya
- UPS: Q3 Earnings Snapshot - WTOP News
- Trump Praises Japan’s New Prime Minister, Saying the US Is an ‘Ally at the Strongest Level'
- Elon Musk's xAI Launches Grok-powered 'Grokipedia' Encyclopedia
- 11 Members of Gakharia’s Party Take MP Seats in Disputed Parliament - Civil Georgia
- Report: Food Companies Are Not Effectively Meeting Demand for Plant-Based Proteins - vegconomist - the vegan business magazine
- In Review: Big-Ass Sword by Andreas Butzbach
- Ecolab: Q3 Earnings Snapshot - WTOP News
- Repligen: Q3 Earnings Snapshot - WTOP News